Literature DB >> 17706534

Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.

Einat Even-Sapir1, Genady Lievshitz, Chava Perry, Yair Herishanu, Hedva Lerman, Ur Metser.   

Abstract

Lymphoma may originate in extranodal sites. Extranodal lymphoma may also be secondary to and accompany nodal disease. Fluorine-18 fluorodeoxyglucose (18F-FDG) imaging has an essential role in the staging of lymphoma, in monitoring the response to therapy, and in detection of recurrence. The introduction of 18F-FDG PET/CT hybrid imaging allows for accurate localization of disease and may be specifically beneficial for the detection of unexpected extranodal sites of disease or exclusion of disease in the presence of nonspecific extranodal CT findings. Accurate staging and localization often dictate the appropriate treatment strategy in patients with lymphoma. Therefore, at any stage in the course of the disease, the potential presence of extranodal disease should be considered when interpreting 18F-FDG PET/CT studies in patients with non-Hodgkin lymphoma and Hodgkin's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706534     DOI: 10.1016/j.rcl.2007.05.009

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  18 in total

1.  Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET.

Authors:  Stephen D Scotti; Jennifer Laudadio
Journal:  J Radiol Case Rep       Date:  2009-08-01

2.  Extensive Extranodal Involvement of Rare Sites in Non Hodgkin's Lymphoma Detected on (18)F- FDG PET-CT: A Case Report.

Authors:  Varun Singh Dhull; Punit Sharma; Suhas Singla; Nauroze Asghar Faizi; Sanjay Thulkar; Chandersekhar Bal; Rakesh Kumar
Journal:  Nucl Med Mol Imaging       Date:  2012-11-09

3.  Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.

Authors:  Özgür Ömür; Yusuf Baran; Aylin Oral; Yeşim Ceylan
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

4.  Fusion PET-CT detection of neurolymphomatosis originating from primary breast lymphoma: A case report and literature review.

Authors:  Liying Xu; Yunfeng Zhou; Dasheng Qiu; Salman Shams
Journal:  Oncol Lett       Date:  2012-08-03       Impact factor: 2.967

5.  131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

Authors:  Naoya Hattori; Ajay K Gopal; Andrew T Shields; Darrell R Fisher; Ted Gooley; John M Pagel; Oliver W Press; Joseph G Rajendran
Journal:  Nucl Med Commun       Date:  2012-12       Impact factor: 1.690

6.  Association between 18F-FDG PET/CT and MRI appearance of spinal leptomeningeal disease before and after treatment at a tertiary referral center.

Authors:  Harry Papasozomenos; Nandita Guha-Thakurta; Rory R Mayer; Jeffrey S Weinberg; Morris D Groves; J Matthew Debnam
Journal:  J Solid Tumors       Date:  2015-10-14

Review 7.  Thyroid nodule as a first manifestation of Hodgkin lymphoma-report of two cases and literature review.

Authors:  Ewelina Szczepanek-Parulska; Malgorzata Szkudlarek; Przemyslaw Majewski; Jan Breborowicz; Marek Ruchala
Journal:  Diagn Pathol       Date:  2013-07-15       Impact factor: 2.644

8.  FDG PET-CT Finding in Bilateral Renal and Bone Involvement of Diffuse Large B-Cell Lymphoma.

Authors:  Yusuf Ziya Tan; Sabire Yılmaz; Meftune Özhan; Metin Halaç
Journal:  Mol Imaging Radionucl Ther       Date:  2014-10-05

9.  Extranodal lymphoma originating in the gluteal muscle with adjacent bone involvement and mimicking a soft tissue sarcoma.

Authors:  Morihiro Katsura; Hirokazu Nishina; Yasushi Shigemori; Takaya Nakanishi
Journal:  Int J Surg Case Rep       Date:  2015-01-15

10.  Bilateral renal involvement in diffuse large B-cell lymphoma on fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Yassir Benameur; Adnane Hammani; Kamal Doghmi; Abderrahim Doudouh
Journal:  World J Nucl Med       Date:  2021-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.